News | September 22, 2008

CryoLife’s Surgical Hemostat Now Available in Canada

September 23, 2008 – CryoLife Inc. announced yesterday that its Hemostase MPH, used to control bleeding in general, cardiac and vascular surgery, is now distributed in Canada through Sorin Group Canada Inc.
Hemostase MPH is developed using Microporous Polysaccharide Hemospheres technology (MPH), which produces a plant-based powder that reportedly rapidly dehydrates blood, and enhances clotting on contact. The Hemostase MPH product received Health Canada approval in 2002, CE Mark approval in 2003 and FDA pre-market approval in 2006.
Available in a convenient ready-to-use applicator, Hemostase MPH, unlike many hemostatic agents, does not require additional operating room preparation or special storage conditions. Pre-clinical studies have shown that Hemostase MPH does not promote infection and absorbs within 24-48 hours of application at the wound site, compared to other surgical hemostats that can take several weeks to fully break down.
When used as a complement to BioGlue surgical adhesive, Hemostase MPH provides surgeons with the ability to quickly and confidently control active bleeding during surgery, a CryoLife executive stated.
For more information: www.cryolife.com

Related Content

nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management | August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
News | Hemostasis Management | January 06, 2016
The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which certain subsidiaries...
Overlay Init